PanTher Therapeutics

Biotechnology ResearchTexas, United States11-50 Employees

PanTher Therapeutics is a clinical-stage oncology company offering transformational localized treatment of cancer.  This is accomplished through its proprietary Sagittari™ platform which enables continuous, high-dose treatment of potent oncology agents exclusively at the site of a tumor.  The Sagittari™ treatment platform is a revolutionary solution for local administration of therapeutic agents.  This foundational technology was invented at the Massachusetts Institute of Technology by PanTher’s founder and CEO.  Sagittari is a polymer-based system that allows therapeutic agents to be formulated in a wide range of dosage forms that can be administered to the surface of a cancerous organ or implanted directly into a tumor.  The drug product is designed to continuously deliver drug for weeks or months at a desired dose level, without unwanted dose-limiting side effects.  PanTher’s lead clinical candidate, PTM-101, has successfully been evaluated in a Phase 1 clinical trial in treatment naïve localized non-metastatic pancreatic cancer patients. PanTher is exploring opportunities to utilize its platform technology in additional solid tumor indications.

Sign up for free to view info

Email Format Employee directory